Table 2.
List of clinical trials combining epigenetic drugs and immunotherapy in melanoma.
| Clinical trial ID | Recruitment status | Phase | Immunotherapy agent | Epigenetic drug | Cancer type |
|---|---|---|---|---|---|
| DNMTi | |||||
| NCT02608437 | Completed | I | Ipilimumab | Guadecitabine | Metastatic melanoma |
| NCT02816021 | Recruiting | II | Pembrolizumab | Azacitidine | Metastatic melanoma |
| NCT05089370 | Not yet recruiting | I/II | Nivolumab | Decitabine/cedazuridine | Mucosal melanoma |
| HDACi | |||||
| NCT02437136 | Unknown | I/II | Pembrolizumab | Entinostat | NSCLC/melanoma, colorectal cancer |
| NCT02697630 | Active | II | Pembrolizumab | Entinostat | Uveal melanoma |
| NCT03765229 | Recruiting | II | Pembrolizumab | Entinostat | Stage III/IV melanoma |
| NCT03903458 | Recruiting | I | Nivolumab | Tinostamustine | Melanoma |
| NCT04133948 | Recruiting | I/II | Ipilimumab and nivolumab | Domatinostat | Stage III melanoma |
| NCT03565406 | Terminated | I | Ipilimumab and nivolumab | Mocetinostat | Stage III/IV melanoma |
| NCT03278665 | Completed | I/II | Pembrolizumab | Domatinostat | Unresectable/metastatic melanoma |
NSCLC, non-small cell lung cancer.